Skip to main content
Log in

Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma

A Canadian National Cancer Institute Clinical Trial Group study

  • Brief Report
  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Leopold WR, Nelson JM, Plowman J,et al.: Anthapyrazoles, a new class of intercalating agents with high level, broad spectrum activity against murine tumors. Cancer Res 45:5532–5539, 1985

    Google Scholar 

  2. Showalter HDH, Johnson JL, Hofteizer JM,et al.: Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. J Med Chem 30(1): 121–131, 1987

    Google Scholar 

  3. Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E, Zee B, Whitfield L: A Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DuP 937). Cancer Research 51:6317–6322, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maroun, J.A., Skillings, J., MacCormick, R. et al. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. Invest New Drugs 11, 235–237 (1993). https://doi.org/10.1007/BF00874163

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874163

Key words

Navigation